Natera Has Acquired From Invitae Certain Assets Relating To Invitae's Non-invasive Prenatal Screening And Carrier Screening Business, For An Upfront Payment Of $10M. In Addition, The Transaction Includes $42.5M In Potential Milestone Payments

1/22/24 7:06:33 AM ET

$NTRA

$NVTA

Medical Specialities

Health Care

Medical Specialities

Health Care

Get the next $NTRA alert in real time by email

Natera Has Acquired From Invitae Certain Assets Relating To Invitae's Non-invasive Prenatal Screening And Carrier Screening Business, For An Upfront Payment Of $10M. In Addition, The Transaction Includes $42.5M In Potential Milestone Payments

Get the next $NTRA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NTRA
$NVTA

Company	Date	Price Target	Rating	Analyst
Natera Inc. $NTRA	6/3/2024	$142.00	Buy	Jefferies
Natera Inc. $NTRA	4/8/2024	$117.00	Buy	Craig Hallum
Natera Inc. $NTRA	2/20/2024	$68.00 → $85.00	Strong Buy → Outperform	Raymond James
Natera Inc. $NTRA	12/29/2023	$75.00 → $85.00	Buy	BTIG Research
Natera Inc. $NTRA	12/14/2023	$70.00	Buy	Guggenheim
Natera Inc. $NTRA	12/13/2023	$70.00	Outperform	Wolfe Research
Natera Inc. $NTRA	11/13/2023	$68.00	Outperform → Strong Buy	Raymond James
Natera Inc. $NTRA	9/28/2023	$48.00	Mkt Perform	Bernstein

More analyst ratings

$NTRA
$NVTA
Press Releases

Fastest customizable press release news feed in the world

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Underscores the Company's commitment to generating robust scientific evidence on its leading MRD technology Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date. In clinical studies, S
11/21/24 5:31:00 PM ET
$NTRA
Medical Specialities
Health Care
Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
11/12/24 4:05:00 PM ET
$NTRA
Medical Specialities
Health Care
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
First-of-its-kind study of >1K patients evaluating the impact of adjuvant treatment escalation in patients tested with Signatera™; results to be presented at ASCO GI in Jan. 2025 Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. CALGB (Alliance)/SWOG 80702 evaluated the benefit of adding celecoxib to FOLFOX in postoperative treatment of stage III colorectal cancer (CRC) in a biomarker unselected population. This pre-specified analysis includes 1,011 CRC patients with available post-surgical plasma samples and investigates Si
11/12/24 7:00:00 AM ET
$NTRA
Medical Specialities
Health Care

$NTRA
$NVTA
Leadership Updates

Live Leadership Updates

Aranscia Acquires YouScript from Invitae
Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc
11/15/23 4:35:00 PM ET
$NVTA
Medical Specialities
Health Care
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu
9/25/23 4:30:00 PM ET
$NVTA
Medical Specialities
Health Care
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
– Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth – SAN FRANCISCO, Aug. 28, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of
8/28/23 4:02:00 PM ET
$NVTA
Medical Specialities
Health Care

$NTRA
$NVTA
Financials

Live finance-specific insights

Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% over the same period. Generated a gross margin of 61.8% in the third quarter of 2024, compared to a gross margin of 45.1% in the third quarter of 2023. Processed approximately 775,800 tests in the third quarter of 2024, compared to approximately 626,000 tests in the third quarter of 2023, an
11/12/24 4:05:00 PM ET
$NTRA
Medical Specialities
Health Care
Natera to Report its Third Quarter 2024 Results on November 12, 2024
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Third Quarter 2024 Financial Results Date: Tuesday, Nov. 12, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webc
11/1/24 9:00:00 AM ET
$NTRA
Medical Specialities
Health Care
Natera Reports Second Quarter 2024 Financial Results
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the same period. Generated a gross margin of 58.8% in the second quarter of 2024, compared to a gross margin of 45.2% in the second quarter of 2023. Processed approximately 760,300 tests in the second quarter of 2024, compared to approximately 617,200 tests in the second quarter of 2023, an incr
8/8/24 4:05:00 PM ET
$NTRA
Medical Specialities
Health Care

$NTRA
$NVTA
Market Insights

Live Market Insights

(NTRA) - Analyzing Natera's Short Interest
Natera's (NYSE:NTRA) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp
7/23/24 2:00:25 PM ET
$NTRA
Medical Specialities
Health Care
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 18.07% on an annualized basis producing an average annual return of 31.07%. Currently, Natera has a market capitalization of $12.47 billion. Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $386.36 today based on a price of $101.57 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
7/18/24 5:00:15 PM ET
$NTRA
Medical Specialities
Health Care
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $13.71 billion. Buying $1000 In NTRA: If an investor had bought $1000 of NTRA stock 5 years ago, it would be worth $4,293.85 today based on a price of $111.64 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
7/4/24 12:00:24 PM ET
$NTRA
Medical Specialities
Health Care

Natera Has Acquired From Invitae Certain Assets Relating To Invitae's Non-invasive Prenatal Screening And Carrier Screening Business, For An Upfront Payment Of $10M. In Addition, The Transaction Includes $42.5M In Potential Milestone Payments

Chat with this insight

Recent Analyst Ratings for $NTRA$NVTA

$NTRA$NVTA SEC Filings

SEC Form 10-Q filed by Natera Inc.

Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Natera Inc.

$NTRA$NVTA Press Releases

Fastest customizable press release news feed in the world

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Natera Reports Third Quarter 2024 Financial Results

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

$NTRA$NVTA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies resumed coverage on Natera with a new price target

Craig Hallum resumed coverage on Natera with a new price target

Natera downgraded by Raymond James with a new price target

$NTRA$NVTA Leadership Updates

Live Leadership Updates

Aranscia Acquires YouScript from Invitae

Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

$NTRA$NVTA Financials

Live finance-specific insights

Natera Reports Third Quarter 2024 Financial Results

Natera to Report its Third Quarter 2024 Results on November 12, 2024

Natera Reports Second Quarter 2024 Financial Results

$NTRA$NVTA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Marcus Gail Boxer sold $1,548,931 worth of shares (9,682 units at $159.98), decreasing direct ownership by 50% to 9,704 units (SEC Form 4)

Director Baynes Roy D. exercised 37,230 shares at a strike of $23.48 and sold $5,439,565 worth of shares (37,230 units at $146.11) (SEC Form 4)

CEO AND PRESIDENT Chapman Steven Leonard sold $677,574 worth of shares (4,628 units at $146.41) and sold $14,635 worth of Common Stok (100 units at $146.35), decreasing direct ownership by 2% to 185,034 units (SEC Form 4)

$NTRA$NVTA Market Insights

Live Market Insights

(NTRA) - Analyzing Natera's Short Interest

Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years

$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today

$NTRA$NVTA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Natera Inc.

SEC Form SC 13G/A filed by Natera Inc. (Amendment)

SEC Form SC 13G/A filed by Natera Inc. (Amendment)

Recent Analyst Ratings for
$NTRA
$NVTA

$NTRA
$NVTA
SEC Filings

$NTRA
$NVTA
Press Releases

$NTRA
$NVTA
Analyst Ratings

$NTRA
$NVTA
Leadership Updates

$NTRA
$NVTA
Financials

$NTRA
$NVTA
Insider Trading

$NTRA
$NVTA
Market Insights

$NTRA
$NVTA
Large Ownership Changes